DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
ASH launches sickle cell disease clinical trials network to accelerate therapy development
ASH launched a clinical trials network designed to accelerate development of novel therapies for patients with sickle cell disease.
The network will match clinical trial sponsors with research sites, facilitate patient recruitment and provide consulting services. A core component will be a centralized data repository developed and maintained by ASH.
“We are on the brink of a new era in sickle cell disease research and treatment. Interest in this disease is expanding, with more than 40 treatments and more than a dozen devices in the research and development pipeline,” ASH President Alexis A. Thompson, MD, MPH, professor of pediatrics in the division of hematology, oncology and stem cell transplantation at Northwestern Medicine and associate director of equity and minority health at Ann and Robert H. Lurie Children’s Hospital of Chicago, said in a press release.
Related Content
-
videos & visuals4 Transition Stages of Sickle Cell Disease and Tips for Each Stagehttps://www.onescdvoice.com/wp-content/u...
-
education & researchDevelopmental Profile of Sleep and Its Potential Impact on Daytime Functioning From Childhood to Adulthood in Sickle...Young individuals with sickle cell anaem...
-
news & eventsSickle-Cell Patients See Hope in CRISPRSickle-cell disease is one of the most c...
-
news & eventsSafety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
-
news & eventsFDA grants CRISPR gene therapy fast track designation for sickle cell diseaseThe FDA granted fast track designation t...
-
news & eventsCrizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
news & eventsAcetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Ga...Acetylon Pharmaceuticals, Inc., the lead...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.